Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures

NCT01913405 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01913405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01913405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
December 20, 2013
Completion date
September 23, 2016
Enrollment
30 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a